Vyxeos
Prescribing
Information (PI) PI
  • THE PATIENTS
  • THE FORMULATION
  • THE DATA
  • THE DOSING
  • THE RESOURCES
  • PI
The resources
the resourcees
Clinical Papers Clinical papers
Phase 3 Study
 Phase 3 Study

Phase 3 Study

SmPC and Prescribing Information are available in the menu

Phase 3 Study
 Phase 3 Study

Italian Real-World Evidence

SmPC and Prescribing Information are available in the menu

Phase 3 Study
 Phase 3 Study

French Real-World Evidence

SmPC and Prescribing Information are available in the menu

German Evidence
 Phase 3 Study

German Real-World Evidence

SmPC and Prescribing Information are available in the menu

Posters
 Phase 3 Study

Post-Hoc Analysis: Phase 3 Exploratory Analysis

SmPC and Prescribing Information are available in the menu

Phase 3 Study
 Phase 3 Study

Five-Year Follow-Up Data

SmPC and Prescribing Information are available in the menu

Animated Clinical Summaries animations
videos
animation

5-Year Follow-Up
Clinical Summary

SmPC and Prescribing Information are available in the menu

videos
animation

Italian Real-World Evidence
Clinical Summary

SmPC and Prescribing Information are available in the menu

videos
animation

French Real-World Evidence
Clinical Summary

SmPC and Prescribing Information are available in the menu

German Real-World Evidence
Clinical Summary

SmPC and Prescribing Information are available in the menu

Downloadable Materials Downloadable materials
Downloadable materials
 Downloadable materials
Information For
Pharmacists
Videos Videos
videos
Mechanism of Action

Mechanism of Action

SmPC and Prescribing Information are available in the menu

videos
Laying the Foundation Toward Long-Term Survival
Laying the Foundation Towards Long-Term Survival
videos
Reinforcing Clinical Results in the Real-World
Reinforcing Clinical Results in the Real-World
  • * High-risk AML is defined as therapy-related acute myeloid leukaemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC)
This website is intended for European Healthcare Professionals only.

ADVERSE EVENTS REPORTING

Adverse events should be reported. Healthcare professionals are asked to report any adverse events via their national reporting system (see Section 4.8 of SmPC). Adverse events should also be reported to Jazz Pharmaceuticals by email to medinfo-int@jazzpharma.com or phone via +353 1 968 1631 (may include an international call charge).

Job code: INT-VYX-2200141
Date of Preparation: May 2023
Vyxeos
Vyxeos
  • Contact Us
  • Terms of
    Use
  • Privacy
    Statement
  • Cookie
    Policy
  • Prescribing
    Information (PI)
You are being directed to the Jazz corporate website.

Follow link
You are being directed to an external website.
Follow link
This Jazz Pharmaceuticals website has been created for healthcare professionals only.

Important notice: This site has been created for healthcare professionals only. By entering this site, you are confirming that you are a European healthcare professional. This site contains promotional information.

I CONFIRM THAT I AM A EUROPEAN HEALTHCARE PROFESSIONAL

I AM A UK HEALTHCARE PROFESSIONAL

I AM A US HEALTHCARE PROFESSIONAL

I AM NOT A HEALTHCARE PROFESSIONAL
You are leaving the vyxeos.eu website.

Please note that this information is intended for healthcare professionals in the UK

https://vyxeos.co.uk
You are leaving the vyxeos.eu website.

Please note that this information is intended for healthcare professionals in the US only

https://vyxeospro.com
For European patients and the general public

For more information:

Patient information leaflet
EMA - Information on Vyxeos Liposomal

By clicking here you will be taken to the European Medicines Agency’s external website

If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly through your national medicines side effect reporting system or to Jazz Pharmaceuticals AEreporting@jazzpharma.com. By reporting side effects, you can help provide more information on the safety of this medicine.